Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Clin Cancer Res. 2011 Nov 16;18(1):127–139. doi: 10.1158/1078-0432.CCR-11-1889

Figure 1.

Figure 1

Figure 1

Figure 1

Figure 1

Figure 1

c-Src inhibition leads to decreased SOCS2 expression and STAT5 activation. (A) Six HNSCC cell lines were incubated with 100 nM dasatinib for 7 hours, and mRNA levels of all the known SOCS molecules were measured by qPCR and expressed as fold control (vehicle treatment). # 6.2-fold control. † SOCS5 was not detectable in four cell lines. *P<0.05. (B) TU167 and Osc19 cell lines were incubated with 100 nM dasatinib for the indicated times, lysed, and analyzed by Western blot analysis with the indicated antibodies. (C–E) TU167 and Osc19 cells were transfected with nontargeting siRNA or c-Src–specific siRNA. The mRNA levels of all the SOCS molecules were measured by qPCR analysis (C–D) or Western blot analysis (E). (F) TU167 and Osc19 cell lines were treated with 100 nM dasatinib for 7 hours, and lysates were subjected to immunoprecipitation with the total STAT5 antibody. Immunoprecipitates were resolved on 8% SDS-PAGE and blotted with the pSTAT5 (Y694) monoclonal antibody. The data in A, C, and D are presented as an average of three replicates; bars indicate the standard deviation. *P<0.05.